Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Eocene

22/11/2023 22:02

* Galmed Pharmaceuticals Ltd  GLMD.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of $-3.15.  The lone analyst forecast for
the quarter was for a loss of 27 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Galmed Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 24 cents​.
    * The company reported a quarterly loss of $1.47 million.
    * Galmed Pharmaceuticals Ltd shares had fallen by 41.9% this
quarter and lost 95.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $1.00 

This summary was machine generated from LSEG data November 22 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.27          -0.24          Beat
 Jun. 30 2023      -0.34          -0.95          Missed
 Mar. 31 2023      -1.50          -1.09          Beat
 Dec. 31 2022      -2.10          -1.50          Beat